Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis

NCT01558245 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT01558245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01558245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis
Lead sponsor
Jinling Hospital, China
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2011
Completion date
December 31, 2013
Enrollment
99 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrovascular disease